Categories: Market Research

Global Leukemia Therapeutics Market Size and Forecast 2024-2033|Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A

The Leukemia Therapeutics by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Leukemia Therapeutics Market:

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

According to The Business Research Company’s Leukemia Therapeutics, The leukemia therapeutics market size has grown strongly in recent years. It will grow from $16.55 billion in 2023 to $17.78 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growth in geriatric population, improved diagnostics leading to early detection of leukemia, increasing prevalence of leukemia, growing investment in research and development, expansion of personalized medicine approaches.

The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $23.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to development of novel immunotherapies for leukemia, growing focus on precision medicine in leukemia treatment, expansion of indications for existing leukemia therapies, increased adoption of gene therapies,

advances in supportive care for leukemia patients. Major trends in the forecast period include integration of biomarker-driven approaches, rise of combination therapies for enhanced efficacy, emphasis on minimal residual disease monitoring, increasing use of car-t cell therapies, exploration of targeted therapies based on leukemia subtypes.

The rising prevalence of leukemia is driving the growth of the leukemia therapeutics market. Leukemia is a type of blood cancer that starts in the bone marrow and proceeds to uncontrolled blood cell growth. The increased accessibility of medical treatment to leukemia patients across the globe and the growing availability of treatment options have contributed to increased demand for leukemia therapeutics. For instance, in January 2023, according to a report published by the American Cancer Society, a US-based health organization, it is anticipated that there will be around 59,610 new instances of leukemia of all types and approximately 23,710 fatalities in 2023 resulting from leukemia of all types in the United States. Additionally, an estimated 20,380 new cases of acute myeloid leukemia (AML) and about 11,310 AML-related deaths are expected in the same year. Therefore, the rising prevalence of leukemia is contributing to the growth of the leukemia therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=6358&type=smp

The leukemia therapeutics market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments

2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia

3) By Molecule Type: Small Molecules, Biologics

4) By End-Users : Hospitals, Homecare, Specialty Clinics, Other End-Users

Combination therapies is new trend gaining popularity in the leukemia therapeutics market. In combination therapies, two or more modalities are tested in combinations with other immunotherapies or targeted therapies that promise to deliver long-term survival benefits that may be unavailable with current approaches. For instance, in September 2021, Dana-Farber Cancer Institute, a US-based cancer treatment, and research institute’s clinical research team reported that a combination of three molecularly targeted drugs including an inhibitor of BCL-2 (venetoclax), a second-generation inhibitor of BTK (acalabrutinib), and a CD20 inhibitor (obinutuzumab) are effective against chronic lymphocytic leukemia (CLL).

The leukemia therapeutics market report table of contents includes:

1. Executive Summary

2. Leukemia Therapeutics Market Characteristics

3. Leukemia Therapeutics Market Trends And Strategies

4. Leukemia Therapeutics Market – Macro Economic Scenario

5. Global Leukemia Therapeutics Market Size and Growth

26. South America Leukemia Therapeutics Market

27. Brazil Leukemia Therapeutics Market

28. Middle East Leukemia Therapeutics Market

29. Africa Leukemia Therapeutics Market

30. Leukemia Therapeutics Market Competitive Landscape And Company Profiles

Top Major Players: